KENNETH MCCLAIN to Middle Aged
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Middle Aged.
Connection Strength
0.180
-
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
Score: 0.040
-
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
Score: 0.030
-
How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
Score: 0.027
-
Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
Score: 0.022
-
A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
Score: 0.015
-
BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 07 10; 146(2):206-218.
Score: 0.014
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
Score: 0.013
-
BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
Score: 0.009
-
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.008
-
Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
Score: 0.003